Related Experiment Video
Updated: Feb 1, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
[Peripheral lamellar keratoplasty in treatment of relapsing pterygium]
S A Malozhen1, S V Trufanov1, D A Krakhmaleva1
1Research Institute of Eye Diseases, 11A Rossolimo St., Moscow, Russian Federation, 119021.
Purpose:
To evaluate the effectiveness and safety of peripheral lamellar keratoplasty (LKP) for treating relapsing pterygium.
Material And Methods:
The study was conducted in the period of 2007-2017 and included 84 patients (91 eyes) with stage II-IV relapsing pterygium. Best corrected visual acuity (BCVA) before the surgery was in average 0.65±0.28 (0.01 to 1.0). Astigmatism varied from 0.5 to 6.5 D (mean 3.41±2.06). All patients underwent pterygium removal surgery followed by LKP. The analyzed parameters included visual acuity, refraction error before and after the surgery, frequency of relapses and post-operative complications.
Results:
The follow-up period was 4 months to 10 years (mean 30.9±25.4 months). BCVA after the surgery was 0.1-1.2 (mean 0.83±0.24), post-operative astigmatism - 0 to 3.5 D (1.08±0.62). BCVA has improved and remained stable in 86 (94.5%) out of 91 eyes, decrease of visual acuity was observed in 5 cases (5.5%). Frequent relapse of pterygium happened in 5 cases (5.5%), was non-progressing and required no surgical treatment.
Conclusion:
LKP is an effective and safe method of surgical treatment of relapsing pterygium that provides good optical, tectonic and anti-relapsing results thanks to barrier properties of the layered transplant.
Related Concept Videos
Peripheral Nervous System: Ganglia and Nerves
Nerves
The nerve is a bundle of axons that serves as the communication highway in the PNS. Each nerve is ensheathed in a protective layer of connective tissue called the epineurium. This outermost layer safeguards the nerve and supports the...
Peripheral Artery Disease I: Introduction
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Treatment Resistant Cancers
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Treatment

